Seven Fleet Capital Management LP Purchases 1,036,500 Shares of CytomX Therapeutics, Inc. $CTMX

Seven Fleet Capital Management LP lifted its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 2,119.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,085,398 shares of the biotechnology company’s stock after buying an additional 1,036,500 shares during the period. CytomX Therapeutics makes up about 1.6% of Seven Fleet Capital Management LP’s portfolio, making the stock its 17th largest position. Seven Fleet Capital Management LP’s holdings in CytomX Therapeutics were worth $5,101,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Schulhoff & Co. Inc. purchased a new stake in CytomX Therapeutics during the fourth quarter valued at approximately $1,597,000. Siren L.L.C. acquired a new stake in CytomX Therapeutics in the first quarter valued at approximately $16,251,000. Eversept Partners LP purchased a new position in CytomX Therapeutics in the fourth quarter worth $10,680,000. Ally Bridge Group NY LLC purchased a new position in CytomX Therapeutics in the first quarter worth $4,230,000. Finally, Elmind Capital LP acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth $2,982,000. Institutional investors own 67.77% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on CTMX. Zacks Research upgraded CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Wall Street Zen upgraded CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reduced their target price on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. Finally, Wolfe Research started coverage on CytomX Therapeutics in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.10.

CytomX Therapeutics Price Performance

CTMX stock opened at $3.10 on Friday. The firm’s fifty day simple moving average is $3.39 and its 200-day simple moving average is $4.31. The company has a market capitalization of $527.59 million, a P/E ratio of -7.56 and a beta of 2.08. CytomX Therapeutics, Inc. has a 12 month low of $1.72 and a 12 month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. The firm had revenue of $10.26 million for the quarter, compared to analyst estimates of $4.68 million. As a group, sell-side analysts forecast that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.